SOLARIS VACCINES, INC.
A whole-cell inactivated vaccine for improved protection against tuberculosis
A whole-cell inactivated vaccine for improved protection against tuberculosis is a funding opportunity from SOLARIS VACCINES, INC., up to 269874, closing July 31, 2027.
Jul 31, 2027
(365d left)Overview
PROJECT SUMMARY/ABSTRACT Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is the world's deadliest infectious disease. Approximately 10.6 million people fell ill from TB in 2022, resulting in 1.6 million deaths globally1. These alarming numbers demonstrate the critical need for effective TB prevention…